A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus
bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS
wild-type tumors.